This content is from: Culture In the Hunt for Fraud, the Red Flags Start With the Auditor With its Adani report, Hindenburg zeroed in on the tiny firm’s thin staff and client roster. By Richard Teitelbaum March 08, 2023
This content is from: Portfolio A Jim Simons Market Mystery — Solved? A secretive investment fund backed by the legendary quant displays a penchant for biotech stocks. There’s a good reason for that. By Richard Teitelbaum February 07, 2023
This content is from: Premium Franklin Templeton Strikes Back at Saba in Closed-End Battle The $1.41 trillion mutual fund giant is issuing preferred stock that dilutes common shareholders’ control at three of its closed-end funds. By Richard Teitelbaum December 15, 2022
This content is from: Premium Off the Shelf: Success From Failure Richard Teitelbaum's "The Most Dangerous Trade: How Short Sellers Uncover Fraud, Keep Markets Honest, and Make and Lose Billions" takes an inside look at the world of professional skeptics. By Michael Peltz December 08, 2015
This content is from: Portfolio An Activist Saba Takes On Franklin Templeton Boaz Weinstein’s Saba Capital, awash in 2022 profits from credit wagers, is now targeting a trio of Franklin closed-end funds. By Richard Teitelbaum November 15, 2022
This content is from: Premium Brevan Howard Flourishes Amid ‘Trussonomic Circus’ The year is shaping up to be one of the best ever for the master of macro mayhem. By Richard Teitelbaum October 26, 2022
